PIRS (Pieris Pharmaceuticals) Pre-Tax Income : $-15.95 Mil (TTM As of Sep. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Pieris Pharmaceuticals Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Pieris Pharmaceuticals's pretax income for the three months ended in Sep. 2024 was $-2.89 Mil. Its pretax income for the trailing twelve months (TTM) ended in Sep. 2024 was $-15.95 Mil. Pieris Pharmaceuticals's pretax margin was %.

During the past 11 years, Pieris Pharmaceuticals's highest Pretax Margin was -55.03%. The lowest was -1179.96%. And the median was -126.41%.

Pieris Pharmaceuticals Pre-Tax Income Historical Data

The historical data trend for Pieris Pharmaceuticals's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pieris Pharmaceuticals Pre-Tax Income Chart

Pieris Pharmaceuticals Annual Data

Trend

Jun14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

Get a 7-Day Free Trial

-25.47

-37.07

-45.74

-33.28

-24.54

Pieris Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Pre-Tax Income	Get a 7-Day Free Trial															-10.75	-4.58	-4.89	-3.59	-2.89

Competitive Comparison of Pieris Pharmaceuticals's Pre-Tax Income

For the Biotechnology subindustry, Pieris Pharmaceuticals's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pieris Pharmaceuticals's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pieris Pharmaceuticals's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Pieris Pharmaceuticals's Pre-Tax Income falls into.

Pieris Pharmaceuticals Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Pieris Pharmaceuticals's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-12.232	+	-14.162	+	0	+	1.851	+	0
	=	-24.54

Pieris Pharmaceuticals's Pretax Income for the quarter that ended in Sep. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-3.135	+	0.079	+	0	+	0.169	+	-4.4408920985006E-16
	=	-2.89

Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.95 Mil.

Pieris Pharmaceuticals (NAS:PIRS) Pre-Tax Income Explanation

Pieris Pharmaceuticals's Pretax Margin for the quarter that ended in Sep. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-2.887	/	0
	=	%

During the past 11 years, Pieris Pharmaceuticals's highest Pretax Margin was -55.03%. The lowest was -1179.96%. And the median was -126.41%.

Pieris Pharmaceuticals Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Pieris Pharmaceuticals's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Pieris Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pieris Pharmaceuticals Inc (NAS:PIRS) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

225 Franklin Street, 26th Floor, Boston, MA, USA, 02110

Website

https://www.pieris.com

Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store, and transport a wide spectrum of molecules. The Company's clinical pipeline consists of immuno-oncology, or IO, bispecifics in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Geographically, all the operations of the firm function through the region of the United States.

Executives

Ann Barbier	director	255 STATE STREET, C/O PIERIS PHARMACEUTICALS,INC., BOSTON MA 02109
Peter A Kiener	director	40 GUEST STREET, BOSTON MA 02135
Maya R. Said	director	C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR, BOSTON MA 02109
Matthew L Sherman	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Christopher P Kiritsy	director
Bvf I Gp Llc	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Shane Olwill	officer: Chief Development Officer	C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR, BOSTON MA 02109
Ahmed Mousa	officer: Chief Business Officer	255 STATE STREET, 9TH FLOOR, C/O PIERIS PHARMACEUTICALS, INC., BOSTON MA 02109
Hitto Kaufmann	officer: Chief Scientific Officer	C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR, BOSTON MA 02109
Thomas Bures	officer: Chief Financial Officer	C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR, BOSTON MA 02109
Tim Demuth	officer: Chief Medical Officer	C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR, BOSTON MA 02109
Aquilo Capital Management, Llc	10 percent owner	ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, SAN FRANCISCO CA 94129
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104